Moderna Stock Rises After Surprise Q3 Profit and Higher 2026 Outlook
Moderna swung to a $162 million third-quarter profit on $1.31 billion of revenue and raised its 2026 sales growth forecast to 15% to 25%. Shares rose about 7% Friday.
Moderna turned a profit in the third quarter and lifted its full-year sales forecast, sending the vaccine maker's stock higher on Friday, November 6, 2026. Revenue rose 29% to $1.31 billion, and the company earned $162 million after losing $200 million a year earlier, according to its results as reported by Investing.com and 24/7 Wall St.
The shares were up 7.29% at 11:01 a.m. ET, StockTitan reported, TheStreet reported an 8.09% premarket gain in a 7:37 a.m. ET update. Prices were still moving during the session.
Moderna Q3 2026: key numbers
Measure | Q3 2026 | Q3 2025 |
|---|---|---|
Revenue | $1.31 billion | $1.01 billion |
U.S. revenue | $780 million | — |
International revenue | $533 million | — |
Net income (loss) | $162 million | ($200 million) |
Earnings per share (adjusted, per Investing.com) | $0.38 | — |
Research and development | $583 million (down 27%) | — |
Source: Moderna's Q3 2026 results as reported by Investing.com and 24/7 Wall St. on November 6, 2026.
Wall Street had expected much less. The revenue consensus was about $891 million to $892 million, the two outlets said, and analysts had been looking for a loss per share. Investing.com said growth came mainly from stronger COVID-19 vaccine sales outside the U.S., helped by deliveries under long-term government agreements.
"We delivered 29% revenue growth in the third quarter," Chief Executive Stéphane Bancel said, as quoted by Investing.com and 24/7 Wall St.
A bigger 2026 forecast
Moderna raised its outlook for the full year:
2026 guidance | New | Previous |
|---|---|---|
Revenue growth | 15% to 25% | Up to 10% |
Cash and investments at year-end | $8.1 billion to $8.3 billion | $4.7 billion to $5.2 billion |
Research and development spending | About $2.7 billion | $2.9 billion |
Pipeline news
- Flu vaccine approval: Moderna said its seasonal flu shot, mFLUSIVA, won U.S. approval, making it the company's fifth approved product globally.
- Skin cancer: intismeran, a melanoma treatment, produced positive Phase 3 results, both outlets reported.
What it means for investors
A quarter of 29% growth and a swing to profit is a notable change from a year earlier. Still, vaccine sales are seasonal and depend heavily on government orders, which can make single quarters look better or worse than the full year. Our guide on how to read an earnings report explains the difference between revenue, net income and guidance.
Moderna was one of Friday's top gainers as markets bounced after Thursday's selloff. See our stock market today story for the bigger picture, and our market cap guide to compare company sizes.
This article is for information only and is not investment advice.
Sources
- Investing.com: Moderna shares surge 10% on earnings beat and raised revenue outlook (November 6, 2026)
- 24/7 Wall St.: Moderna climbs 5% as surprise profit and raised outlook beat forecasts (November 6, 2026)
- TheStreet: Stock Market Today, Nov. 6, 2026
- StockTitan: The Stock Market Today Live, November 6, 2026
This article is for information only and is not investment advice. Do your own research before buying or selling any asset.